107 related articles for article (PubMed ID: 26169035)
1. BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species.
Wang J; Liu L; Cen J; Ji B
Chem Biol Interact; 2015 Sep; 239():139-45. PubMed ID: 26169035
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the P-glycoprotein relevant for multidrug resistance by intracellular acidification through the crosstalk of MAPK signaling pathways.
Jin W; Lu Y; Li Q; Wang J; Zhang H; Chang G; Lin Y; Pang T
Int J Biochem Cell Biol; 2014 Sep; 54():111-21. PubMed ID: 25043687
[TBL] [Abstract][Full Text] [Related]
4. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
Ji BS; He L
J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
[TBL] [Abstract][Full Text] [Related]
5. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
6. Miltirone Is a Dual Inhibitor of P-Glycoprotein and Cell Growth in Doxorubicin-Resistant HepG2 Cells.
Zhou X; Wang Y; Lee WY; Or PM; Wan DC; Kwan YW; Yeung JH
J Nat Prod; 2015 Sep; 78(9):2266-75. PubMed ID: 26339922
[TBL] [Abstract][Full Text] [Related]
7. PHII-7 inhibits cell growth and induces apoptosis in leukemia cell line K562 as well as its MDR- counterpart K562/A02 through producing reactive oxygen species.
Peng H; Yuan X; Shi R; Wei X; Ren S; Yan C; Ding Y; Lin Y; Fan D; Yang M; Zhang Y; Xiong D
Eur J Pharmacol; 2013 Oct; 718(1-3):459-68. PubMed ID: 23911883
[TBL] [Abstract][Full Text] [Related]
8. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Ji BS; He L; Liu GQ
Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
[TBL] [Abstract][Full Text] [Related]
9. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Wang S; Wang L; Chen M; Wang Y
Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
[TBL] [Abstract][Full Text] [Related]
10. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
[TBL] [Abstract][Full Text] [Related]
11. Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells.
Meshkini A; Yazdanparast R
Exp Toxicol Pathol; 2012 May; 64(4):357-65. PubMed ID: 21074392
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.
Zhao YY; Yu L; Liu BL; He XJ; Zhang BY
Mol Med Rep; 2015 Nov; 12(5):7335-43. PubMed ID: 26459009
[TBL] [Abstract][Full Text] [Related]
13. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
14. Aromatic heterocyclic esters of podophyllotoxin exert anti-MDR activity in human leukemia K562/ADR cells via ROS/MAPK signaling pathways.
Zhang L; Zhang Z; Chen F; Chen Y; Lin Y; Wang J
Eur J Med Chem; 2016 Nov; 123():226-235. PubMed ID: 27484511
[TBL] [Abstract][Full Text] [Related]
15. 6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance.
Liu B; Qiu Q; Zhao T; Jiao L; Li Y; Huang W; Qian H
ChemMedChem; 2015 Feb; 10(2):336-44. PubMed ID: 25470220
[TBL] [Abstract][Full Text] [Related]
16. Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Wang JY; Li YJ
Oncol Rep; 2016 Jun; 35(6):3659-68. PubMed ID: 27109742
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.
Ramos AM; Fernandez C; Amrán D; Esteban D; de Blas E; Palacios MA; Aller P
J Cell Physiol; 2006 Dec; 209(3):1006-15. PubMed ID: 16972261
[TBL] [Abstract][Full Text] [Related]
18. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of P-glycoprotein expression by sustained intracellular acidification in K562/Dox cells.
Lu Y; Pang T; Wang J; Xiong D; Ma L; Li B; Li Q; Wakabayashi S
Biochem Biophys Res Commun; 2008 Dec; 377(2):441-446. PubMed ID: 18851949
[TBL] [Abstract][Full Text] [Related]
20. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P
Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
